Related Experiment Video
Updated: Jan 18, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Immune rejection in a humanized model of murine prostate cancer
Dörthe Schaue1, Richard C Koya, Yu-Pei Liao
1Department of Radiation Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1714, USA.
Background/Aim:
We attempted to develop a humanized mouse model for prostate cancer to study immune recognition and responses to human prostate-tumor antigens in mice.
Materials And Methods:
Our study was based on cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) tumors. TRAMP cells were modified to express a chimeric MHC I molecule comprising the extracellular domains of human HLA-A2.1 with the transmembrane and intracellular domain of K(b).
Results:
These modified TRAMP cells were immunologically rejected following recognition of human tumor epitopes known to be immunodominant in the context of HLA-A2.1. Immune-compromised SCID-beige mice did not reject these tumors.
Conclusion:
We conclude that epitopes derived from endogenous murine homologs were being presented by the chimeric MHC class I molecules due to a lack of central tolerance to these epitopes in the mice.
